• Traverse
    • Timmerman Traverse for Damon Runyon 2026
    • Past Climbs (2018-2025)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for Damon Runyon 2026
    • Past Climbs (2018-2025)
  • The Long Run Podcast
  • About
    • Speaking
    • Podcast
    • Events
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
20
Jun
2016

Going Public at Beaten Down Valuations? The Crossover Hangover

/
Luke Timmerman
/
0
/
All, Finance, Venture Capital
20 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Jun
2016

Opioid Kickbacks Exposed, Infinity Crashes & Merck’s PD-1 Extends Lives

/
Luke Timmerman
/
0
/
All
17 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Jun
2016

The Schreiberians: Where Are They Now?

/
Luke Timmerman
/
0
/
All, People
14 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Jun
2016

BIO Loves Newt: A Backdoor Into a Trump Administration?

/
Luke Timmerman
/
0
/
All, People, Politics
13 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Jun
2016

BIO Jabs Payers, the Sarepta Plot Thickens, & Merck Buys Afferent

/
Luke Timmerman
/
1
/
All
10 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Jun
2016

Silicon Valley Joins the Drug and Device Discovery Party

/
Lisa Suennen
/
0
/
All, Strategy
07 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Jun
2016

Is Bigger Better in Biotech Venture Capital?

/
Luke Timmerman
/
0
/
All, Venture Capital
06 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Jun
2016

ASCO Preview, BioMarin’s Costly DMD Write-Off, & A Superbug Wakeup Call

/
Luke Timmerman
/
0
/
All
03 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
Jun
2016

Fantasy Drug Development: Fleshing out a Cool Way to Test Your Wits in the Biopharma Game

/
Kyle Serikawa
/
1
/
All
02 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
May
2016

Regeneron’s Generosity, Minerva’s Breakout, & Sarepta Waits

/
Luke Timmerman
/
1
/
All, People
27 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
May
2016

Sexism in Biotech: Be Aware, and Stay Vigilant

/
Luke Timmerman
/
1
/
All
23 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
May
2016

Genentech Enters the PD-L1 Arena, Theranos in Ashes & the ASCO PR Machine Revs Up

/
Luke Timmerman
/
0
/
All
20 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
May
2016

I-O: Who’s Doing What? (Part 2)

/
Luke Timmerman
/
0
/
All, Cancer, Drugs
19 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
May
2016

Immuno-Oncology: Who’s Doing What?

/
Luke Timmerman
/
1
/
All, Cancer, Drugs
16 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
May
2016

John Oliver’s Rant, the Sid Mukherjee Tempest & A Lung Cancer Mea Culpa

/
Luke Timmerman
/
0
/
All, Drugs
13 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
May
2016

How Distributed R&D Could Spark Entrepreneurship in Biopharma

/
Kyle Serikawa
/
0
/
All, Drugs, Politics
11 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
9
May
2016

Bull Market or Bubble? Watch My Chat with Biotech Leaders at Milken Global

/
Luke Timmerman
/
0
/
All, Drugs, Payers, Politics
09 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
May
2016

Prince Puts a Face on Opioids, IMS Buys Quintiles & Sarepta Running Wild

/
Luke Timmerman
/
0
/
All
06 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
2
May
2016

How Much Scrutiny is Biopharma Facing? Not as Much as You Might Think

/
Luke Timmerman
/
0
/
All, Politics, The Edge
02 May 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Apr
2016

Congress Slaughters Hogs, Sarepta’s Bad Day & Soon-Shiong’s 9-Figure Payday

/
Luke Timmerman
/
0
/
All
29 Apr 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 72 73 74 75 76 … 83 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2026, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder